Description

ARA-290 (Cibinetide)

ARA-290, also known as Cibinetide, is a synthetic 11-amino acid peptide derived from the helix-B domain of Erythropoietin (EPO). It is uniquely engineered to retain the potent tissue-protective and anti-inflammatory properties of EPO while completely devoid of its hematopoietic (red blood cell stimulating) effects.

At Guardian Labs, we provide ARA-290 in a highly stable, lyophilized format. Every batch is rigorously tested via HPLC to guarantee >99% purity, ensuring that your research into neuropathic pain and inflammation is based on the highest quality standards.

What is ARA-290?

ARA-290 was developed to solve a major limitation in cytokine research: how to utilize the healing potential of Erythropoietin without causing dangerous thickening of the blood (polycythemia).

By isolating the specific structural region of EPO that interacts with tissue repair receptors, scientists created ARA-290. This peptide has a short half-life but initiates long-lasting biological signaling cascades involved in cellular survival and the reduction of inflammation.

Mechanism of Action: The Innate Repair Receptor

The primary target of ARA-290 is the Innate Repair Receptor (IRR).

• Selective Binding: The IRR is a heterocomplex formed by the EPO receptor and the beta-common receptor (CD131). Unlike the standard EPO receptor, the IRR is typically not expressed in healthy tissue but is upregulated rapidly during times of cellular stress, injury, or inflammation.

• Anti-Inflammatory Response: When ARA-290 binds to the IRR, it inhibits pro-inflammatory cytokines (such as TNF-alpha) and activates anti-apoptotic (cell survival) pathways. This makes it a highly specific tool for targeting damaged tissue without affecting healthy systems.

  ---

Potential Research Applications

ARA-290 is currently one of the most promising peptides in the field of neurology and immunology. Key areas of investigation include:

• Small Fiber Neuropathy (SFN): Studies are examining ARA-290’s ability to promote the regrowth of small nerve fibers and reduce pain signals in sarcoidosis and diabetes models.

• Chronic Inflammation: Researching the peptide’s efficacy in downregulating systemic inflammation in autoimmune conditions.

• Ischemic Protection: Investigating its role in protecting heart and kidney tissue from damage caused by restricted blood flow (ischemia-reperfusion injury).

  ---

Scientific References

To validate the specific mechanism of this non-hematopoietic peptide, we reference the following peer-reviewed studies.

1. Small Fiber Neuropathy in Sarcoidosis

Summary: This clinical trial investigated the effects of ARA-290 in patients with sarcoidosis-associated small fiber neuropathy. The results demonstrated that the peptide significantly improved corneal nerve fiber density (a marker of nerve regeneration) and reduced reported pain symptoms compared to placebo.

• View the study on PubMed

2. Distinction from Erythropoietin (EPO)

Summary: This foundational research outlines how the “helix-B” domain of EPO (which ARA-290 mimics) is responsible for tissue protection, distinct from the domain responsible for red blood cell production. It confirms that ARA-290 activates the Innate Repair Receptor without stimulating hematopoiesis.

• View the study on PubMed

3. Neuropathic Pain & Diabetes

Summary: Studies in Type 2 diabetic models have shown that ARA-290 administration can alleviate allodynia (pain from non-painful stimuli) and prevent the loss of intra-epidermal nerve fibers. This suggests a potential neuroprotective role in metabolic diseases.

• View the study on PubMed

  ---

Product Specifications

• Sequence: pyroGlu-Glu-Val-Gln-Leu-Leu-Lys-Lys-Arg-Leu-Gln-Leu-Lys-His-Trp-Ser-Arg-Trp-Gly-Cys-Cys-Thr-Ile-Ala

• Format: Lyophilized Powder (Freeze-dried)

• Vial Size: 4mg / 16mg

• Purity: >99% (HPLC Verified)

• Storage: Store at -20°C. Reconstitute with Bacteriostatic Water.

  ---

  Disclaimer: All products listed on this site are for laboratory research and development purposes only. They are not intended for human consumption, diagnostic, or therapeutic use. Customers must be at least 18 years old to purchase.